RECENT MODALITIES IN DRUG DELIVERY VIA INHALATION THERAPY – AN ADVANCED TREATMENT STRATEGY FOR PULMONARY CARCINOMA
Keywords:
Nanoparticles, Inhalation drug delivery, Pulmonary targeted therapyAbstract
The potential benefit of nanoparticles (NPs) as a colloidal delivery system for pharmaceutical relevance has earned substantial concern in the past decades. Fatality rate due to cancer sustained to hike; advances in nanotechnology have quite become a trenchant approach for enhancing effective drug targeting to cancer tissues by circumventing all the imperfections of traditional chemotherapy. Inhalation drug delivery directly targeting the lungs through respiratory tract is a rapidly maturing field of research and most recently explored approaches for both local and systemic therapy. With the recent advances in synthesis and manipulation of nanoparticles, inhalation drug delivery has shown great impact on pulmonary practice. Inhalation drug delivery has diverse actions over traditional chemotherapy including a) non-invasive b) avoiding first pass metabolism and systemic toxicity c) minimized frequent dosing and d) target delivery of drug to the lung epithelium thereby enhancing local drug concentrations. Dry powder inhalers, meter dose inhalers and nebulizers are some few efficient methods to deliver therapeutic agents directly targeting to the lungs. The ultimatum of inhalation therapy is to generate particles with an ample range of particle sizes. With the recent interest in the development of pulmonary targeted therapy, this review presents how the inhalation drug delivery overcomes conventional chemotherapy and focuses the recent treatment modalities that have been established for pulmonary carcinoma by the route of inhalation as well as discusses the advantages of inhalation drug delivery.
Â
Downloads
References
Proctor R. Tobacco and the global lung cancer epidemic. Nat Rev Cancer 2001;1(1):82-6.
Carballo M, Maish M, Jaroszewski D, Holmes C. Video-assisted thoracic surgery (VATS) as a safe alternative for the resection of pulmonary metastases: a retrospective cohort study. J Cardiothoracic Surgery 2009;4(1):13.
Goto H, Yano S, Zhang H, Matsumori Y, Ogawa H, Blakey DC, et al. Vascular-targeting activity of ZD6126 against primary pancreatic tumour growth and lymph node metastasis following orthotopic tumour cell injection in a nude mouse model. Eur J Cancer 2002;38:S40.
Ames B, Gold L. The causes and prevention of cancer: the role of environment. Biotherapy 1998;11:205-20.
Smith L, Denissenko M, Bennett W. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. JNCI 2000;92(10):803-11.
Hecht S, Upadhyaya P, Wang M, Bliss R, McIntee E, Kenney P. Inhibition of lung tumorigenesis in A/J mice by N acetyl-S-(N-2-phenethylthiocarbamoyl)-L-cysteine and myo-inositol, individually and in combination. Carcinogenesis 2002;23:1455-61.
Tseng C, Su W, Yen K, Yang K, Lin F. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials 2009;30(20):3476-85.
Burris H. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. Oncogene 2009;28:S4-13.
Wauthoz N, Deleuze P, Hecq J. In vivo assessment of temozolomide local delivery for lung cancer inhalation therapy. Eur J Pharm Sci 2010;39(5):402-11.
Garbuzenko O, Saad M, Pozharov V, Reuhl K, Mainelis G, Minko T. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci 2010;107(23):10737-42.
Tseng C, Wu S, Wang W. Targeting efficiency and bio-distribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. Biomaterials 2008;29(20):3014-22.
Courrier H, Butz N, Vandamme T. Pulmonary drug delivery systems: recent developments and prospects. Crit Rev Ther Drug Carrier Syst 2002;19(4-5):425-98.
Groneberg D, Witt C, Wagner U, Chung K, Fischer A. Fundamentals of pulmonary drug delivery. Res Med 2003;97(4):382-7.
Patton J, Byron P. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discovery 2007;6(1):67-74.
Hukkanen J, Pelkonen O, Hakkola J, Raunio H. Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit Rev Toxicol 2002;32(5):391-411.
Van der Schans C, Postma D, Koater G, Rubin B. Physiotherapy and bronchial mucus transport. Eur Respir J 1999;13(6):1477-86.
Geiser M. Update on macrophage clearance of inhaled micro-and nanoparticles. J Aerosol Med Pulm Drug Delivery 2010;23(4):207-17.
Labiris N, Dolovich M. Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56(6):600-12.
Shevchenko I, Resnik G. Inhalation of chemical substances and oxygen in radiotherapy of bronchial cancer. Neoplasma 1968;15:419-26.
Selting K, Waldrep J, Reinero C. Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the Aero Probe® intracorporeal nebulization catheter. J Aerosol Med Pulm Drug Delivery 2008;21(3):255-68.
Yan Y, Cook J, McQuillan J. Chemopreventive effect of aerosolized polyphenon E on lung tumorigenesis in A/J mice. Neoplasia 2007;9(5):401-5.
Corcoran T. Inhaled delivery of aerosolized cyclosporine. Adv Drug Delivery Rev 2006;58(9-10):1119-27.
Kalantarian P. Preparation of 5-fluorouracil nanoparticles by supercritical antisolvents for pulmonary delivery. Int J Nanomed 2010;5:763-70.
Tatsumura T, Koyama S, Tsujimoto M, Kitagawa M, Kagamimori S. Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: fundamental and clinical. Br J Cancer 1993;68:1146-9.
Huland E, Heinzer H, Huland H. Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon α in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment. J Cancer Res Clin Oncol 1994;120(4):221-8.
Huland E, Burger A, Fleischer J. Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2:an outcome study. Folia Biol 2003;49:183–90.
Kim I, Byeon H, Kim T. Doxorubicin-loaded highly porous large PLGA microparticles as a sustained-release inhalation system for the treatment of metastatic lung cancer. Biomaterials 2012;33(22):5574-83.
Anabousi S, Bakowsky U, Schneider M, Huwer H, Lehr C, Ehrhardt C. In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer. Eur J Pharm Sci 2006;29(5):367-74.
Borm P, Kreyling W. Toxicological hazards of inhaled nanoparticles-potential Implications for drug delivery. J Nanosci Nanotech 2004;4(5):521-31.
Patlolla R, Chougule M, Patel A, Jackson T, Tata P, Singh M. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J. Controlled Release 2010;144(2):233-41.
Yu J, Chien Y. Pulmonary drug delivery: Physiologic and mechanistic aspects. Crit Rev Ther Drug Carrier Syst 1997;14(4):395-43.
Lai S, Wang Y, Wirtz D, Hanes J. Micro-and macrorheology of mucus. Adv Drug Delivery Rev 2009;61(2):86-100.
Lai S, Wang Y, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Delivery Rev 2009;61(2):158-71.
Van der Schans C. Bronchial mucus transport. Respir Care 2007;52:1150-8.
Brain J. Inhalation, deposition and fate of insulin and other therapeutic proteins. Diabetes Technol Ther 2007;9(s1):S4-15.
Swift D. Aerosols and humidity therapy. Generation and respiratory deposition of therapeutic aerosols. Am Rev Respir Dis 1980;122:71-7.
Phipps P, Gonda I, Anderson S, Bailey D, Bautovich G. Regional deposition of saline aerosols of different tonicities in normal and asthmatic subjects. Eur Respir J 1994;7(8):1474-82.
Shinohara H. Distribution of lymphatic stomata on the pleural surface of the thoracic cavity and the surface topography of the pleural mesothelium in the golden hamster. Anat Rec 1997;249(1):16-23.
Lai-Fook S. Mechanical factors in lung liquid distribution. Annu Rev Physiol 1993;55(1):155-79.
Deffebach M, Charan N, Lakshminarayan S, Butler J. The bronchial circulation. Small, but a vital attribute of the lung. Am Rev Respir Dis 1987;135:463-81.
Olschewski H, Simonneau G, Galie N. Inhaled iloprost for severe pulmonary hypertension. ACC Curr J Rev 2002;11(6):19.
Gessler T, Seeger W, Schmehl T. Inhaled prostanoids in the therapy of pulmonary hypertension. J Aerosol Med Pulm Drug Delivery 2008;21(1):1-12.
Langer R. New methods of drug delivery. Sci 1990;249(4976):1527-33.
Rogueda P, Traini D. The nanoscale in pulmonary delivery. Part 2:formulation platforms. Expert Opin Drug Delivery 2007;4(6):607-20.
Sung J, Pulliam B, Edwards D. Nanoparticles for drug delivery to the lungs. Trends Biotechnol 2007;25(12):563-70.
Azarmi S, Roa W, Labenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Delivery Rev 2008;60(8):863-75.
Rytting E, Nguyen J, Wang X, Kissel T. Biodegradable polymeric nanocarriers for pulmonary drug delivery. Expert Opin Drug Delivery 2008;5(6):629-39.
Yang W, Peters J, Williams R. Inhaled nanoparticles-A current review. Int J Pharm 2008;356(1-2):239-47.
Lebhardt T, Roesler S, Beck-Broichsitter M, Kissel T. Polymeric nanocarriers for drug delivery to the lung. J Drug Delivery Sci Technol 2010;20(3):171-80.
Ruge C, Kirch J, Lehr C. Pulmonary drug delivery: from generating aerosols to overcoming biological barriers, therapeutic possibilities and technological challenges. Lancet Respir Med 2013;1(5):402-13.
Patton J. Unlocking the opportunity of tight glycaemic control. Innovative delivery of insulin via the lung. Diabetes Obes Metab 2005;7(s1):S5-8.
Byron PR. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci 1986;75(5):433-8.
Edwards D, Dunbar C. Bioengineering of therapeutic aerosols. Annu Rev Biomed Eng 2002;4:93-107.
Musante C, Schroeter J, Rosati J, Crowder T, Hickey A, Martonen T. Factors affecting the deposition of inhaled porous drug particles. J Pharm Sci 2002;91(7):1590-600.
Vincent J, Johnston A, Jones A, Bolton R, Addison J. Kinetics of deposition and clearance of inhaled mineral dusts during chronic exposure. Occup Environ Med 1985;42(10):707-15.
Newman S, Killip M, Pavia D, Moran F, Clarke S. The effect of changes in particle size on the deposition of pressurized inhalation aerosols. Int J Pharm 1984;19(3):333-7.
Martonen T, katz I. Deposition patterns of polydisperse aerosols within human lungs. J Aerosol Med 1993;6(4):251-74.
Byron PR. Drug delivery via the respiratory tract. J Aerosol Med 1993;6:51-5.
Tsapis N, Bennett D, Jackson B, Weitz D, Edwards D. Trojan particles: Large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci 2002;99(19):12001-5.
Gill S, Labenberg R, Ku T, Azarmi S, Roa W, Prenner E. Nanoparticles: Characteristics, mechanisms of action, and toxicity in pulmonary drug delivery A Review. J Biomed Nanotechnol 2007;3(2):107-19.
Kreyling W. Lung deposition and biokinetics of inhaled nanoparticles. Pneumol 2013;67(12).
Scharch S, Gehr P, Im Hof V, Geiser M, Green F. Surfactant displaces particles toward the epithelium in airways and alveoli. Respir Physiol 1990;80(1):17-32.
Geiser M, Schurch S, Gehr P. Effect of nebulizer type and antibiotic concentration on device performance. J Appl Physiol 2015;94:1793-801.
Weber A, Morlin G, Cohen M, Williams E,ÂWarren J, Ramsey B, Smith A. Effect of nebulizer type and antibiotic concentration on device performance. Pediatric Pulmonol 1997;23(4):249-60.
Eschenbacher W, Boushey H, Sheppard D. Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone. Am Rev Respir Dis 1984;129(2):211-5.
Clement-Duchene C, Alla F, Gauchotte G. Is there a relationship between the presence of lung mucosa preinvasive lesions and lung cancer incidence? Influence of tobacco consumption. Lung Cancer 2014;84(2):134-8.
Paranjpe M, Maller Goymann C. Nanoparticle-mediated pulmonary drug delivery: A Review. IJMS 2014;15(4):5852-73.
Sung J, Pulliam B, Edwards D. Nanoparticles for drug delivery to the lungs. Trends Biotechnol 2007;25(12):563-70.
Vyas S, Khatri K. Liposome-based drug delivery to alveolar macrophages. Expert Opin Drug Delivery 2007;4(2):95-9.
Jaspart S, Bertholet P, Piel G, Dogna J, Delattre L, Evrard B. Solid lipid microparticles as a sustained release system for pulmonary drug delivery. Eur J Pharm Biopharm 2007;65(1):47-56.
Xiang Q, Wang M, Chen F. Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles. Arch Pharmacal Res 2007;30(4):519-25.
Muller R. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 2000;50(1):161-77.
Barthelemy P, Laforat J, Farah N, Joachim J. Compritol 888 ATO: an innovative hot-melt coating agent for prolonged-release drug formulations. Eur J Pharm Biopharm 1999;47(1):87-90.
Baviskar D, Amritkar A, Chaudhari H, Jain D. Modulation of drug release from nanocarriers loaded with a poorly water soluble drug (flurbiprofen) comprising natural waxes. Pharmazie 2012;67(8):701-5.
Nassimi M, Schleh C, Lauenstein H. A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. Eur J Pharm Biopharm 2010;75(2):107-16.
Nassimi M, Schleh C, Lauenstein H. Low cytotoxicity of solid lipid nanoparticles in invitro and exvivo lung models. Inhalation Toxicol 2009;21(s1):104-9.
Paranjpe M, Neuhaus V, Finke J. In vitro and exvivo toxicological testing of sildenafil-loaded solid lipid nanoparticles. Inhalation Toxicol 2013;25(9):536-43.
Silva L, Kasten G, de Campos C, Chinelatto A, Lemos-Senna E. Preparation and characterization of quercetin-loaded solid lipid microparticles for pulmonary delivery. Powder Technol 2013;239:183-92.
Ma P, Dong X, Swadley C. Development of Idarubicin and Doxorubicin solid lipid nanoparticles to overcome pgp-mediated multiple drug resistance in leukemia. J Biomed Nanotechnol 2009;5(2):151-61.
Agu R, Ugwoke M, Armand M, Kinget R, Verbeke N. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res 2001;2:198-209.
Sakagami M. Systemic delivery of biotherapeutics through the lung: opportunities and challenges for improved lung absorption. Ther Delivery 2013;4(12):1511-25.
Mussi S, Silva R, Oliveira M, Lucci C, Azevedo R, Ferreira L. New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles. Eur J Pharm Sci 2013;48(1-2):282-90.
Choi W, Kim J, Choi S, Park J, Ahn W, Kim C. Low toxicity of cationic lipid-based emulsion for gene transfer. Biomaterials 2004;25(27):5893-903.
Nguyen J, Steele T, Merkel O, Reul R, Kissel T. Fast degrading polyesters as siRNA nano-carriers for pulmonary gene therapy. J Controlled Release 2008;132(3):243-51.
Davaran S, Asgari D, Davaran S. Preparation and in vitro evaluation of doxorubicin-loaded Fe3O4 magnetic nanoparticles modified with biocompatible copolymers. Int J Nanomed 2012;7:511-26.
Kong D, Liu J, Liu. Int J Nanomed 2010;6:59-69.
Chen Y, Tsai C, Huang P. Methotrexate conjugated to gold nanoparticles inhibits tumor growth in a syngeneic lung tumor model. Mol Pharm 2007;4(5):713-22.
Chon H, Lee S, Son S, Oh C, Choo J. Highly sensitive immunoassay of lung cancer marker carcinoembryonic antigen using surface-enhanced raman scattering of hollow gold nanospheres. Anal Chem 2009;81(8):3029-34.
Chiu G, Tan Liu, Chang Lim. Perorally active nanomicellar formulation of quercetin in the treatment of lung cancer. Int J Nanomed 2012;7:651-61.
Craparo E, Teresi G, Bondia M, Licciardi M, Cavallaro G. Phospholipid polyaspartamide micelles for pulmonary delivery of corticosteroids. Int J Pharm 2011;406(1-2):135-44.
Bouissou C, Rouse J, Price R, Van der Walle C. The Influence of surfactant on PLGA microsphere glass transition and water sorption: Remodeling the surface morphology to attenuate the burst release. Pharm Res 2006;23(6):1295-305.
Jain R. The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide) (PLGA) devices. Biomaterials 2000;21(23):2475-90.
Ruhe P, Boerman O, Russel F, Spauwen P, Mikos A, Jansen J. Controlled release of rhBMP-2 loaded poly (dl-lactic-co-glycolic acid)/calcium phosphate cement composites invivo. J Controlled Release 2005;106(1-2):162-71.
Wu X, Wang N. Synthesis, characterization, biodegradation, and drug delivery application of biodegradable lactic/glycolic acid polymers. Part II: Biodegradation. J Biomater Sci Polym Ed 2001;12(1):21-34.
Sengupta S, Eavarone D, Capila I. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005;436(7050):568-72.
Guthi J, Yang S, Huang G. MRI-visible micellar nanomedicine for targeted drug delivery to lung cancer cells. Mol Pharm 2010;7(1):32-40.
Okamoto H, Shiraki K, Yasuda R, Danjo K, Watanabe Y. Chitosan-interferon-β gene complex powder for inhalation treatment of lung metastasis in mice. J Controlled Release 2011;150(2):187-95.
Okamoto H, Nishida S, Todo H, Sakakura Y, Iida K, Danjo K. Pulmonary gene delivery by chitosan-pDNA complex powder prepared by a supercritical carbon dioxide process. J Pharm Sci 2003;92(2):371-80.
Lv P, Wei W, Yue H, Yang T, Wang L, Ma G. Porous Quaternized chitosan nanoparticles containing paclitaxel nanocrystals improved therapeutic efficacy in NSCLC after Oral Administration. Biomacromolecules 2011;12(12):4230-9.
Ventura C, Cannava C, Stancanelli R. Gemcitabine-loaded chitosan microspheres. Characterization and biological in vitro evaluation. Biomed Microdevices 2011;13(5):799-807.
Mousa S, Bharali D, Khalil M, Gurbuz M, Simone. Nanoparticles and cancer therapy: A concise review with emphasis on dendrimers. Int J Nanomed 2009;4:1-7.
Starpharma: News. http://www.starpharma.com/news/150 (2013). [Last accessed 10 May 2013].
Taratula O, Garbuzenko O, Kirkpatrick P. Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J Controlled Release 2009;140(3):284-93.
Rahbek U, Nielsen A, Dong M. Bioresponsive hyperbranched polymers for siRNA and miRNA delivery. J Drug Targeting 2010;18(10):812-20.
Kong D, Liu J, Liu. Novel peptide-dendrimer conjugates as drug carriers for targeting non small NSCLC. Int J Nanomed 2010;6:59-69.
Gautam A, Densmore C, Melton S, Golunski E, Waldrep J. Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis. Cancer Gene Ther 2002;9(1):28-36.
Jiang H, Hong Kim. Suppression of lung cancer progression by biocompatible glycerol triacrylate and spermine-mediated delivery of shAkt1. Int J Nanomed 2012;7:2293-306.
Zhou X, Li X, Gou M. Antitumoral efficacy by systemic delivery of heparin conjugated polyethylenimine-plasmid interleukin-15 complexes in murine models of lung metastasis. Cancer Sci 2011;102(7):1403-9.
Kleemann E, Neu M, Jekel N. Nano-carriers for DNA delivery to the lung based upon a TAT-derived peptide covalently coupled to PEG-PEI. J Controlled Release 2005;109(1-3):299-316.
Jere D, Xu C, Arote R, Yun C, Cho M, Cho C. Poly(β-amino ester) as a carrier for si/shRNA delivery in lung cancer cells. Biomaterials 2008;29(16):2535-47.
Xu P, Yin Q, Shen J. Synergistic inhibition of breast cancer metastasis by silibinin-loaded lipid nanoparticles containing TPGS. Int J Pharm 2013;454(1):21-30.
Li M, Neoh K, Wang R, Zong B, Tan J, Kang E. Methotrexate-conjugated and hyperbranched polyglycerol-grafted Fe3O4 magnetic nanoparticles for targeted anticancer effects. Eur J Pharm Sci 2013;48(1-2):111-20.
Gill K, Nazzal S, Kaddoumi A. Paclitaxel loaded PEG5000 DSPE micelles as pulmonary delivery platform: Formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation. Eur J Pharm Biopharm 2011;79(2):276-84.
Chen, Zhao, Dong, Zhang. Paclitaxel-loaded poly(glycolide-co-ε-caprolactone)-b-D-α-tocopheryl polyethylene glycol 2000 succinate nanoparticles for lung cancer therapy. Int J Nanomed 2013;8:1947-57.
Yang R, Yang S, Shim W. Lung-specific delivery of paclitaxel by chitosan-modified PLGA nanoparticles via transient formation of microaggregates. J Pharm Sci 2009;98(3):970-84.
Rao A, Shrikhande S, Bajaj A. Development of cisplatin nanoparticles as dry powder inhalers for lung Cancer. Curr Nanosci 2013;9(4):447-50.
Roa W, Azarmi S, Al-Hallak M, Finlay W, Magliocco A, Labenberg R. Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. J Controlled Release 2011;150(1):49-55.
Kang K, Chun M, Kim O. Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomed Nanotechnol Biol Med 2010;6(2):210-13.
Doijad R, Manvi F, Godhwani D, Joseph R, Deshmukh N. Formulation and targeting efficiency of cisplatin engineered solid lipid nanoparticles. Indian J Pharm Sci 2008;70(2):203.
Potta S, Minemi S, Nukala R. Preparation and characterization of ibuprofen solid lipid nanoparticles with enhanced solubility. J Microencapsulation 2011;28(1):74-81.
Hu K, Huang C, Hwu J, Su W, Shieh D, Yeh C. ChemInform abstract: a new photothermal therapeutic agent: Core-free nanostructured Au x Ag 1-x Dendrites. ChemInform 2008;39:27.
Yoon T, Yu K, Kim E. Specific targeting, cell sorting, and bioimaging with smart magnetic silica core-shell nanomaterials. Small 2006;2(2):209-15.
Carlson C, Hussain S, Schrand A. Unique cellular interaction of silver nanoparticles: size-dependent generation of reactive oxygen species. J Phys Chem B 2008;112(43):13608-19.
Venkatesan B, Subramanian V, Tumala A, Vellaichamy E. Rapid synthesis of biocompatible silver nanoparticles using aqueous extract of Rosa damascena petals and evaluation of their anticancer activity. Asian Pac J Trop Biomed 2014;7:S294-S300.
Rajendran R, Ganesan N, Balu Sk, Alagar S, Thandavamoorthy P and Thiruvengadam D. Green synthesize, characterization, antimicrobial and cytotoxic effects of silver nanoparticles using O. heracleoticum L. leaf extract. Int J Pharm Pharm Sci 2015;7(4):288-93.
Zou Y, Tornos C, Qiu X, Lia M, Perez-Soler R. p53 Aerosol formulation with low toxicity and high efficiency for early lung cancer treatment. Clin Cancer Res 2007;13(16):4900-8.
Koshkina N. Biodistribution and pharmacokinetics of aerosol and intravenously administered DNA-polyethyleneimine complexes: optimization of pulmonary delivery and retention. Mol Ther 2003;8(2):249-54.
Kaul G, Amiji M. Tumor-targeted gene delivery using poly (ethylene glycol)-modified gelatin nanoparticles: in vitro and in vivo studies. Pharm Res 2005;22:951-61.
Almeida A, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Delivery Rev 2007;59(6):478-90.
Bivas-Benita M, Oudshoorn M, Romeijn S. Cationic submicron emulsions for pulmonary DNA immunization. J Controlled Release 2004;100(1):145-55.
Ziady A. Transfection of airway epithelium by stable PEGylated poly-lysine DNA nanoparticles in vivo. Mol Ther 2003;8(6):936-47.
Minati L, Antonini V, Dalla Serra M, Speranza G. Multifunctional branched gold-carbon nanotube hybrid for cell imaging and drug delivery. Langmuir 2012;28(45):15900-6.
Lodhi N, Mehra N, Jain N. Development and characterization of dexamethasone mesylate anchored on multi walled carbon nanotubes. J Drug Targeting 2013;21(1):67-76.
Arya N, Arora A, Vasu K, Sood A, Katti D. Combination of single walled carbon nanotubes/graphene oxide with paclitaxel: a reactive oxygen species mediated synergism for treatment of lung cancer. Nanoscale 2013;5(7):2818.
Hou C, Chen C, Hou S, Li Y, Lin F. The fabrication and characterization of dicalcium phosphate dihydrate-modified magnetic nanoparticles and their performance in hyperthermia processes in vitro. Biomaterials 2009;30(27):4700-7.
Zhang Y, Kim W, Huang L. Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy. Biomaterials 2013;34(13):3447-58.
Li J, Yang Y, Huang L. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J Controlled Release 2012;158(1):108-14.
Yang S, Sun J, Liu C. Ex vivo magnetofection with magnetic nanoparticles: A novel platform for non-viral tissue engineering. Artif Organs 2008;32(3):195-204.
Sukumar U, Bhushan B, Dubey P, Matai I, Sachdev A, Packirisamy G. Emerging applications of nanoparticles for lung cancer diagnosis and therapy. Int Nano Lett 2013;3(1):45.
Newman S. Aerosol generators and delivery systems. Respir Care 1991;36:939-51.
Thompson P. Drug delivery to the small airways. Am J Respir Crit Care Med 1998;157(5):S199-202.
Co, Boe J, dennis J. European respiratory society guidelines on the use of nebulizers. Guidelines prepared by a European respiratory society task force on the use of nebulizers. Eur Respir J 2001;18(1):228-42.
Kendrick A, Smith E, Wilson R. Selecting and using nebuliser equipment. Thorax 1997;52(Suppl 2):92-2.
Smith E, Denyer J, Kendrick A. Comparison of twenty three nebulizer/compressor combinations for domiciliary use. Eur Respir J 1995;8(7):1214-21.
Niven R, Ip A, Mittelman S, Prestrelski S, Arakawa T. Some factors associated with the ultrasonic nebulization of proteins. Pharm Res 1995;12(1):53-9.
Kleinstreuer C, Zhang Z, Li Z. Modeling airflow and particle transport/deposition in pulmonary airways. Respir Physiol Neurobiol 2008;163(1-3):128-38.
Kleinstreuer C, Zhang Z, Donohue J. Targeted drug-aerosol delivery in the human respiratory system. Ann Rev Biomed Eng 2008;10(1):195-20.
Tiano S, Dalby R. Comparison of a respiratory suspension aerosolized by an air-jet and an ultrasonic nebulizer. Pharm Dev Technol 1996;1(3):261-8.
Brocklebank D, Ram F, Wright J. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess 2001;5(26):1-149.
Siddiqui M, Plosker G. Novolizer-Multidose dry powder inhaler. Am J Drug Delivery 2006;4(1):57-60.
Kahler D. Novolizer®. Curr Opin Pulm Med 2003;9:S11-6.
Terzano C. Dry powder inhalers and the risk of error. Respir 2008;75(1):14-5.
Labiris N, Dolovich M. Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56(6):600-12.
Lavorini F, Magnan A, Christophe Dubus J. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med 2008;102(4):593-604.
Dolovich M. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest 2005;127(1):335.
Yeo L, Gagnon Z, Chang H. AC electrospray biomaterials synthesis. Biomaterials 2005;26(31):6122-8.
Gomez A. The electrospray and its application to targeted drug inhalation. Respir Care 2002;47(12):1419-31.
Marijnissen J. Electro hydrodynamic atomization and its applications. J Aerosol Sci 2004;35:3-4.
Dunne A, O'Hara T, Devane J. A new approach to modeling the relationship between in vitro and in vivo drug dissolution/absorption. Stat Med 1999;18(14):1865-76.
Zierenberg B. Optimizing the invitro performance of respimat. J Aerosol Med 1999;12(s1):S19-24.
Newman S, Steed K, Reader S, Hooper G, Zierenberg B. Efficient delivery to the lungs of flunisolide aerosol from a new portable hand held multidose nebulizer. J Pharm Sci 1996;85(9):960-4.
Newman S. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines. Chest 1998;113(4):957.
Bateman E, Tashkin D, Siafakas N. A one-year trial of tiotropium Respimat® plus usual therapy in COPD patients. Respir Med 2010;104(10):1460-72.
Wattenberg L. Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol. Carcinogenesis 2000;21(2):179-82.
Alan R, Irma M. Inhaled isotretinoin (13-cis Retinoic Acid) is an effective lung cancer chemopreventive agent in A/J mice at low doses: a pilot study. Clin Cancer Res 2015;6:3015-24.
Fulzele S, Chatterjee A, Shaik M, Jackson T, Singh M. Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic NSCLC xenograft model. Pharm Res 2006;23(9):2094-106.
Haynes A, Shaik M, Chatterjee A, Singh M. Formulation and evaluation of aerosolized celecoxib for the treatment of lung cancer. Pharm Res 2005;22(3):427-39.
Jin H, Xu C, Kim H. Urocanic acid-modified chitosan-mediated PTEN delivery via aerosol suppressed lung tumorigenesis in K-rasLA1 mice. Cancer Gene Ther 2008;15(5):275-83.
Ichite N, Chougule M, Patel A, Jackson T, Safe S, Singh M. Inhalation delivery of a novel diindolylmethane derivative for the treatment of lung cancer. Molecular Cancer Ther 2010;9(11):3003-14.
Taratula O, Garbuzenko O, Chen A, Minko T. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J Drug Targeting 2011;19(10):900-14.
Wang Z, Chen H, Roa W, Finlay W. Farnesol for aerosol inhalation; Nebulization and activity against human lung cancer cells. J Pharm Pharm Sci 2003;6(1):95-100.
Cappuzzo F. Gemcitabine for the treatment of advanced NSCLC. OTT; 2009. p. 209.
Lemarie E, Vecellio L, Hureaux J. Aerosolized gemcitabine in patients with carcinoma of the lung: Feasibility and safety study. J Aerosol Med Pulm Drug Delivery 2011;24(6):261-70.
Hillman G, Younes E, Visscher D. Systemic treatment with interleukin-4 induces regression of pulmonary metastases in a murine renal cell carcinoma model. Cell Immunol 1995;160(2):257-63.
Night V, Kleinerman E, Waldrep J, Giovanella B, Gilbert B, Koshkina N. 9-Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice. Ann N Y Acad Sci 2000;922(1):151-63.
Koshkina N, Kleinerman E. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int J Cancer 2005;116(3):458-63.
Ho-Young Lee, Young-Ah Suh, Lee J. Inhibition of oncogenic K-ras signaling by aerosolized gene delivery in a mouse model of human lung cancer. Clin Cancer Res 2002;8:2970-5.
Hershey A, Kurzman I, Forrest L. Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model J Aerosol Med Pulm Drug Delivery 1999;21(1):61-9.
Otterson G, Villalona-Calero M, Hicks W. Phase I/II Study of Inhaled doxorubicin combined with platinum-based therapy for advanced NSCLC. Clin Cancer Res 2010;16(8):2466-73.
Zarogoulidis P, Eleftheriadou E, Sapardanis I. Feasibility and effectiveness of inhaled carboplatin in NSCLC patients. Invest New Drugs 2011;30(4):1628-40.
Tatsumura T, Yamamoto K, Murakami A, Tsuda M, Sugiyama S. New chemotherapeutic method for the treatment of tracheal and bronchial cancers-nebulization chemotherapy. Gan No Rinsho 1983;29(7):765-70.
Wattenberg L. Chemoprevention of cancer of the upper respiratory tract of the Syrian golden hamster by aerosol administration of difluoromethylornithine and 5-fluorouracil. Cancer Res 2004;64(7):2347-9.
Hitzman C, Elmquist W, Wiedmann T. Development of a respirable, sustained release microcarrier for 5-fluorouracil II: In vitro and in vivo optimization of lipid coated nanoparticles. J Pharm Sci 2006;95(5):1127-43.
Koshkina N, Knight V, Gilbert B, Golunski E, Roberts L, Waldrep J. Improved respiratory delivery of the anticancer drugs, camptothecin and paclitaxel, with 5% CO 2-enriched air: pharmacokinetic studies. Cancer Chemother Pharmacol 2001;47(5):451-6.
Koshkina N, Golunski E, Roberts L, Gilbert B, Knight V. Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice. J Aerosol Med 2004;17(1):7-14.
Wittgen B, Kunst P, Perkins W, Lee J, Postmus P. Assessing a system to capture stray aerosol during inhalation of nebulized liposomal cisplatin. J Aerosol Med 2006;19(3):385-91.
Wittgen B, Kunst P, van der Born K. Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin Cancer Res 2007;13(8):2414-21.
Hohenforst-Schmidt W, Zarogoulidis P, Linsmeier B. Enhancement of aerosol cisplatin chemotherapy with gene therapy expressing ABC10 protein in respiratory system. J Cancer 2014;5(5):344-50.
Gagnadoux F, Le Pape A, Urban T. Safety of pulmonary administration of gemcitabine in rats. J Aerosol Med 2005;18(2):198-206.
Gagnadoux F, Leblond V, Vecellio L. Gemcitabine aerosol: in vitro antitumor activity and deposition imaging for preclinical safety assessment in baboons. Cancer Chemother Pharmacol 2005;58(2):237-44.
Min R, Li T, Du J, Zhang Y, Guo J, Lu W. Pulmonary gemcitabine delivery for treating lung cancer: pharmacokinetics and acute lung injury aspects in animals. Can J Physiol Pharmacol 2008;86(5):288-98.
Ozeki T, Tagami T. Drug/polymer nanoparticles prepared using unique spray nozzles and recent progress of inhaled formulation. Asian J Pharm Sci 2014;9(5):236-43.
Azarmi S, Tao X, Chen H. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int J Pharm 2006;319(1-2):155-61.
Otterson G, Villalona-Calero M, Sharma S. Phase I study of inhaled doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res 2007;13(4):1246-52.
Lawson K, Anderson K, Snyder R. Novel vitamin E analogue and 9-nitro-camptothecin administered as liposome aerosols decrease syngeneic mouse mammary tumor burden and inhibit metastasis. Cancer Chemother Pharmacol 2004;54(5):421-31.
Rajan B, Sathish S, Jayakumar S. Synthesis and invitro anticancer evaluation of 2-isopropyl-5-methylphenol Loaded PLGA based iron oxide nanoparticles. Biomed Prev Nut 2014;4(2):137-41.
Rajan B, Sathish S, Balakumar S, Devaki T. Synthesis and dose interval dependent hepatotoxicity evaluation of intravenously administered polyethylene glycol-8000 coated ultra-small superparamagnetic iron oxide nanoparticle on Wistar rats. Environ Toxicol Pharmacol 2015;39(2):727-35.